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Abstract
Background: Genome-wide association studies of pooled DNA samples were shown to be a valuable tool to identify
candidate SNPs associated to a phenotype. No such study was up to now applied to childhood allergic asthma, even if the
very high complexity of asthma genetics is an appropriate field to explore the potential of pooled GWAS approach.
Methodology/Principal Findings: We performed a pooled GWAS and individual genotyping in 269 children with allergic
respiratory diseases comparing allergic children with and without asthma. We used a modular approach to identify the most
significant loci associated with asthma by combining silhouette statistics and physical distance method with cluster-
adapted thresholding. We found 97% concordance between pooled GWAS and individual genotyping, with 36 out of 37
top-scoring SNPs significant at individual genotyping level. The most significant SNP is located inside the coding sequence
of C5, an already identified asthma susceptibility gene, while the other loci regulate functions that are relevant to bronchial
physiopathology, as immune- or inflammation-mediated mechanisms and airway smooth muscle contraction. Integration
with gene expression data showed that almost half of the putative susceptibility genes are differentially expressed in
experimental asthma mouse models.
Conclusion/Significance: Combined silhouette statistics and cluster-adapted physical distance threshold analysis of pooled
GWAS data is an efficient method to identify candidate SNP associated to asthma development in an allergic pediatric
population.
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Introduction
Asthma is a chronic respiratory disease resulting from a
complex interaction of multiple genetic and environmental factors.
In the past decades, more than 200 asthma candidate genes have
been identified using genetic association studies, positional cloning
and knockout mouse approaches [1], but only in the recent years it
has been possible to perform whole-genome investigations largely
due to the genome-wide association studies (GWAS) [2–4], that
have soon shown to be powerful tool to identify novel loci and
susceptibility variants for common diseases.
Genome-wide association studies of pooled DNA samples were
shown to be a valuable tool to identify in a fast, scalable and
economical way candidate SNPs associated to a phenotype [5–7].
This method was applied to different SNP-array platforms and
different diseases and QTL phenotypes, particularly those related to
complex traits as intellectual and psychological abilities, multiple
sclerosis or Alzheimer disease [8–13]. Many tools and analysis
pipelines have also been developed to improve the ability to identify
true associations among thousands of potential candidates [10,14–16].
However, very few studies evaluated the efficacy of different methods
in selecting candidate SNPs for second-stage validation, invariably
reporting a high percentage of false positive results.
No study was up to now applied to allergic asthma, even if the
very high complexity of asthma genetics is an appropriate field to
explore the potential of pooled GWAS approach. This high
complexity ensues from the frequent causal association of asthma
with several other allergic phenotypes that may constitute a
complex confounding factor for the identification of asthma
susceptibility genes in the classical case-control design of GWAS
(asthmatic vs healthy subjects).
To address both these issues, in this study we performed a
pooled GWAS on pediatric allergic asthma, comparing asthmatic
children to allergic subjects, and introducing a new method of
analysis that incorporate silhouette statistics with quality control,
physical distance and cluster-adapted thresholding, that reached
97% efficiency in selecting significant susceptibility loci associated
to allergic asthma onset.
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Pediatric patients cohort
A total of 269 children of white European descent, aged 6–18
years, with a diagnosis of allergic asthma and/or allergic
rhinoconjunctivitis (RC) visited at outpatient clinic of Pediatric
Allergologic Unit were included in the study. Patients were
divided into two groups: patients with asthma (also including
patients with both allergic asthma and rhinoconjunctivitis) and
patients with rhinoconjunctivitis (RC), affected by allergic rhinitis
or rhinoconjunctivitis who had never shown asthmatic symptoms.
The mean age at the blood sampling was 10.663.6 yrs for asthma
group and 9.863.7 for RC group (Table 1). Among patients
included into asthma group, 95.33% developed asthmatic symptoms
before 10 years of age and this evidence is confirmed by the most
recent Italian and European studies which show that a percentage
around 90%ofsubjectswith fullblownasthmabecome symptomatic
before 10 years of age [17,18]. Consequently we can assume that
patients included in the RC group have a very low probability to
develop asthma.
An independent validation set, including 35 patients with
asthma and 44 with rhinoconjunctivitis (RC), was selected in a
second stage of the study. Clinical, allergometric and spirometric
characteristics of the patients were comparable to the ones
included in the first stage of the study.
Ethics Statement
The study was conducted according to the principles expressed
in the Declaration of Helsinki, and approved by Ethic Committee
of University Hospital – S. Orsola-Malpighi of Bologna (AllerGene
protocol no. 134/2008/U/Tess). Written informed consent was
obtained from all the parents or guardians of the minors involved
in the study.
Allergometric assays
Patients’ allergometric assessment was evaluated through the
determination of specific IgE levels (UNICAP1000, Phadia,
Uppsala, Sweden) and by performing Skin Prick tests (Lofarma,
Milan, Italy). Skin prick tests were performed for the main
inhalant allergens: Grass pollen, Parietaria mix, Compositae mix, birch
pollen, hazelnut pollen, D. pteronyssinus, D. farinae and Alternaria a.,
Cladosporium, cat’s epithelium and dog’s dandruff. Referring to the
ACAAI Practice Parameters [19] wheals with a diameter $
histamine (described as ++for a convention) was considered
positive. For each patient total IgE and specific IgE for the main
inhalant (Cynodon d., Phleum p., Ambrosia e., Artemisia v., Parietaria J.,
Betula v., Corylus a., Olea e., D. pteronyssinus, D. farinae, Alternaria a.,
dog’s dandruff, cat’s epithelium) were determined; we considered
positive specific IgE values higher than 1 kU/L to avoid
immunological cross-reactivity. Only the sensitization for the most
represented allergens has been reported (Table 1).
Assessment of pulmonary status of patients
Pulmonary status of patients was evaluated by performing
spirometric tests (ZAN100, nSpire Health GmbH, Germany). In
asthmatic children lung function tests were performed both for
diagnostic purposes and to establish the efficacy of pharmacolog-
ical therapy (inhalatory corticosteroids), while in patients with RC
to exclude a silent pulmonary inflammatory condition. Measure-
ments of lung function were performed both for asthmatic and non
asthmatic children and spirometric parameters were evaluated as
variation between values at baseline and after administration of
rapid-acting bronchodilator (e.g. after 200–400 mg salbutamol),
both to demonstrate the reversibility of lung function abnormal-
ities and to exclude an eventual airflow limitation also in patient
with normal value at baseline. The measured variables were
evaluated according to the GINA guidelines [20] and were
Table 1. Clinical, allergometric and spirometric characteristics of all the children included in the study.
Asthma
135 pts
RC
134 pts p value OR
Age at blood sampling – mean 6 SD (yrs) 10.663.6 9.863.7 NS -
Onset age – mean 6 SD (yrs) 5.262.8 6.263.1 NS -
Sex (male/female) 2.65 1.44 0.02 1.84
Atopic Dermatitis (%) 24.4 31.3 NS -
Other allergic manifestations (%) 15.6 14.2 NS -
Total IgE – g. mean (kU/L) 423.6 245.9 0.0003 -
Phleum p. – sIgE g. mean (kU/L) 18.4 18.7 NS -
Phleum p. – sIgE + (%) 74.1 69.4 NS -
Grass pollen – SPT + (%) 72.6 70.9 NS -
D.pteronyssinus - sIgE g. mean (kU/L) 6.6 3.1 0.02 -
D. pteronyssinus – sIgE + (%) 39.3 21.6 0.002 2.34
D. pteronyssinus –S P T+ (%) 39.3 21.6 0.002 2.34
Baseline FVC % 101.2616.0 104.0611.4 NS -
Baseline FEV1/FVC % 98.968.6 105.569.1 0.0005 -
D FEV1 % 5.665.2 2.364.5 0.002 -
Patientswere divided into Asthmagroup and RC group, detectedat enrolment. Allergic sensitization wasreported for the maininhalantallergens: grass pollens (Phleum p.)
and house dust mites (D. pteronyssinus) both as specific IgE and Skin Prick test. Main spirometric parameters were expressed as rate of predicted values (%). D FEV1 is the
difference in FEV1 values before and after salbutamol administration.
doi:10.1371/journal.pone.0016912.t001
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FVC (forced vital capacity), FEV1 (forced expiratory volume in
one second), FEV1/FVC ratio (Table 1).
Clinical statistical analysis
Statistical significance for age at blood sampling and onset age
of symptoms was evaluated by performing Mann Whitney test.
The Chi squared test was performed to calculate the significance
of gender differences, prevalence of atopic dermatitis and other
allergic manifestations and the prevalence of sensitization to the
major inhalant allergens, for which Odds Ratio (OR) was also
estimated. Total and specific IgE values, expressed as geometric
mean, were evaluated by Fisher exact test. Values of P,0.05 were
considered as significant. Spirometric measurements were report-
ed as average values and their significance was evaluated by Mann
Whitney test (Table 1).
Power analysis
Sample dimension was calculated by modeling the LD
coefficient (D’) as a function of the genetic distance between the
associated marker allele and the disease locus (assuming the worst-
case scenario of the disease locus being located midway between
two markers) and of the number of generations elapsed (G) since
the mutation was introduced. G was chosen as representative of an
outbred population (G=500), and the recombination fraction
between marker and disease locus was estimated from the number
of markers on the array (roughly 500,000).
Sample dimension was then estimated, assuming a frequency of
the predisposing allele of 0.15, a disease prevalence of 0.4
(prevalence of asthma in the allergic population is $40%) [21], a
genotype relative risk of 1.7 (for both the homozygote and
heterozygote), and a marker frequency of 0.2 (taken from
Affymetrix product description). Under these conditions it is
possible to identify such a susceptibility allele with a statistical
power of 80%, a type I error rate of 0.05, and a study of 136 cases
and 136 controls. The estimates were calculated using the Genetic
Power Calculator web tool [22].
DNA extraction and sample pooling
DNA was extracted from all the blood samples with Nucleospin
DNA kit (Macherey & Nagel, Duren, Germany) and individual
DNA concentration was determined in triplicate with the Quant-
iT Pico-Green dsDNA Assay Kit (Invitrogen, Milan, Italy). These
triplicate values were used to calculate a mean concentration for
each sample. Samples were excluded from the analysis if the
coefficient of variation between the three replicates was ,0.1.
DNA samples were assigned to the Asthma group if displaying
symptoms of asthma, alone or associated to other allergic
phenotypes, including RC, and assigned to the RC group if
displaying rhinitis or rhinoconjunctivits alone or associated to
other allergic phenotypes, excluding asthma. Each of the two
groups was subdiveded into 4 independent groups of samples, each
containing 31-36 individuals. Individual DNA samples were then
added to their respective pools in equivalent molar amounts. The
design of multiple replicate pools of distinct individuals was chosen
as it decreases quantification error by reducing quantification
error variance proportionally to the number of times a single pool
is independently constituted (3 times), and measurement error
variance by the number of independent analysis (24 times) [23].
Genome Wide SNP genotyping
Pooling was performed three times to account for pipetting
variability. Each of these replicates was genotyped on Mapping
500K arrays (Affymetrix, Santa Clara; CA) following manufac-
turer’s instructions. Detection rates were calculated with GTYPE
4.1 (Affymetrix) using the MPAM (Modified Partitioning Around
Medoids) MDR algorithm, that represents the number of SNPs that
passes the MPAM discrimination filter/total number of SNPs.
MDR 6 SD was 98.361.8. Raw data were deposited in the GEO
repository with the GSE24481 reference number.
Analysis of pooled SNP genotyping data
Probe intensity data was taken directly from the CEL file and
used to calculate a Relative Allele Signal (RAS) score by the
MPAM algorithm implemented in the SNP-MaP script (http://
sgdp.iop.kcl.ac.uk/oleo/affy). This method calculates the average
of RAS1 (sense) and RAS2 (antisense) values as a quantitative
index of allele frequencies in pooled DNA [6].
Probes were filtered by overall average RAS (0.1,RAS,0.9)
and AAD (Average Absolute Difference, AAD,0.28) to exclude data
with low Minor Allele Frequency and high variability.
To control for possible confounding bias due to population
stratification we applied Principal Component Analysis (PCA) on
the RAS values from the Top 500 ancestry-informative SNPs
identified by Drineas et al. [24], selected from a subset Population
Reference Sample (POPRES) representative of 11 different
populations and analyzed on Mapping 500K arrays (Affymetrix).
PCA was done also in comparison to allele frequencies in CEU,
YRI, CHB and JPT population taken from Hapmap data.
We used silhouette score [25,26] to assess SNP significance.
Silhouette score is a measure to quantify the goodness of data
clustering, defined as the average silhouette calculated over all
cluster elements. For the i-th cluster element, silhouette is defined
as
si~
bi{ai
max ai,bi ðÞ
where ai is the average (Manhattan) distance of the i-th element
from each element of the cluster, and bi is the average distance
over the other clusters (in our case we have only two clusters,
Asthma and RC). Silhouette values range from –1 (bad clustering)
to 1 (optimal clustering).
We chose not to use an F test statistics because very probably
the RAS values (ranging from 0 to1) and in particular the extreme
values, do not fulfil the condition of gaussianity necessary for the
application of the test. Also the absolute values of the differences
were not considered since they do not take into account sample
variability.
For the first step of our analysis we considered 1% top-scoring
probes (about 3000 probes selected). We decided not to choose a
too conservative threshold for single-probe significance (e.g. by
comparison with silhouette values of label-reshuffled data) but we
tried to evaluate a multi-probe significance by looking at the
presence of significant SNP ‘‘blocks’’ (i.e. clustered together along
the chromosome) that likely reflect the presence of LD blocks
including a large number of (even weakly) significant probes. We
evaluated the robustness of our results considering different
starting datasets (5000 and 7000 top-scoring probes) and different
parameters for clustering (chromosomal distance threshold from
20 Kb to 35 Kb, see below) obtaining a good agreement in the
final SNP lists.
SNPs were mapped onto the Human Reference Sequence hg19
GrCh37 assembly (UCSC Genome Browser). Then we clustered
probes with genomic distance ,30 Kb, and we considered only
probes belonging to at least a 2-probe cluster. For cluster
crossvalidation, we assigned randomly the calculated silhouettes
Pooled GWAS Analysis on Pediatric Allergic Asthma
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calculating average cluster silhouette for each cluster size (100
times): average cluster silhouette obtained by reshuffling was
compared to the real average cluster silhouette values, producing
the final list of significant SNPs.
Validation of candidate SNPs
The LD structure of the significant clusters was visualized by
GOLD heatmap and analyzed using Haploview software v. 4.1.
on Caucasian phased genotypes from the International Hapmap
Project (www.hapmap.org). SNAP tool (SNP annotation and
proxy search) was used to find genes proxy to significant SNP
clusters by Linkage Disequilibrium, by setting r
2 threshold to 0.8
and distance to 500 Kb, on Hapmap 22 release data (http://www.
broadinstitute.org/mpg/snap/). For each cluster average silhou-
ette score was reported.
Genotyping of the Top scoring SNPs for the validation study
was performed using the MassArray system on a Sequenom
MALDI-TOF device (Sequenom Inc., San Diego, CA) on the
entire dataset. Primer sequences and PCR conditions are available
upon request. Call rate was 100% for all SNPs and samples
analyzed. SNPs were assessed for Hardy-Weinberg equilibrium
and analyzed by a two-sided Fisher exact test to compare allele
and genotype frequencies between cases and controls. Strength of
association was estimated by conditional OR 695%CI. Quality
controls and allelic and genotypic association tests were performed
using the SNPator package (http://www.snpator.org). Genotyping
of the 24 top scoring SNPs associated with known genes was also
performed on the Sequenom system for the independent
validation set.
Gene expression
Gene expression analysis was performed on GSE6858 and
GSE1301 Gene Expression Omnibus databases (http://www.
ncbi.nlm.nih.gov/geo/), that report gene expression profiling data
on two relevant mouse models of experimental asthma, analyzed
on MG430 2.0 and MOE430A Affymetrix arrays, respectively.
The first analyzes experimental asthma induced in BALB/c mice
by sensitization and challenge with the allergen ovalbumin [27],
while the second one explores the response of whole lungs of
BALB/c mice to asthma induced by house dust mite sensitization
and challenge, vs control mice. CEL files were downloaded,
normalized with rma algorithm and filtered based on gene
expression level (.5 in the log2 scale, at least 50% of samples)
and InterQuartile Range (IQR .10% of average total IQR).
Differential genes between allergen-challenged and control mice
were selected by a modified t-test implemented in limma package
[28], with P,0.05 cutoff. Probe sets corresponding to mouse
orthologs of human genes were identified by the Affymetrix
annotation in the NetAffx database.
Results
We recruited 269 children of self-reported white European
ancestry, aged 6 to 18 years with a well documented diagnosis of
allergic asthma and/or rhinoconjunctivitis (RC). Clinical, phenotypic
and spirometric data of the subjects recruited in the AllerGene study
are summarized in Table 1. Among the patients of the two groups
no differences in the prevalence of atopic dermatitis and other
allergic manifestations could be highlighted, while male gender
was associated with asthmatic phenotype (P=0.02, OR 1.84).
Asthmatic patients have higher total IgE values (P=0.0003),
higher specific IgE values (P=0.02) and higher prevalence of
sensitization to house dust mite (P=0.002) than patients with RC
without asthmatic symptoms. According to pulmonary function
tests at baseline, no differences in FVC were underlighted between
Asthma and RC groups, while asthmatic patients showed a lower
value of FEV1/FVC (P=0.0005). Spirometric tests performed
after administration of salbutamol revealed significant higher
variation of FEV1 in patients with asthma (P=0.002).
GWAS analysis by SNP arrays was undertaken on pooled DNA
samples from 269 subjects of the study participants on the
Mapping 500K Affymetrix platform. Patients were classified into
Asthma (135) and RC (134) groups, and further subdivided into 4
subgroups considered biological replicates. Pooling was performed
in triplicate, to account for technical variability (Figure 1). This
multiple-pool strategy optimizes the power of the analysis by
reducing the variance of each source of experimental error [23].
To control for possible stratification bias due to population
structure we applied Principal Component Analysis to a list of 500
top scoring SNPs identified as ancestry-informative in a subset of
the Population Reference Sample [24]. PCA showed that there is
no recognizable substructure inside our data (Asthma and RC pools
are mixed up), suggesting that no bias related to population
structure was inflated into the data (Figure S1 in File S1). As
expected the distribution of allele frequencies inside the pools is
compatible with CEPH ancestry (Northern and Western europe-
an, Figure S1 in File S1).
Data reliability was assessed by checking Pearson correlation
coefficient C among samples: technical replicates resulted more
correlated among themselves (C.0.96). We also checked single
probe average variance a) for triplicates, b) for classes (Asthma/RC)
and c) for all arrays, confirming data homogeneity (ma=0.21;
mb=0.23; mc=0.25; sa=0.54; sb=0.62; sc=0.58) (Figure S2
in File S1).
Probes were then filtered by overall average RAS (Relative Allele
Signal) and AAD (Average Absolute Difference) to exclude data with low
Minor Allele Frequency and excessive variability (78.6% selection)
(Figure S3 in File S1).
RAS values were analyzed by a Silhouette score statistic, that
empirically showed to perform well in pooled-GWAS studies [14],
and mapped to the human Reference Sequence hg19 assembly.
Significant SNPs were selected as clusters of top 1% significant
silhouette scores within a genomic distance of 30 Kb, and
crossvalidated to control for type I errors by random reshuffling
average silhouette scores. Only clusters showing an average
silhouette score above the cluster-adapted threshold were called
significant (Figure 2).
Of the 113 significant clusters identified, SNPs representative of
the first 37 clusters selected as the top-scoring (Silhouette P,0.001)
were validated by individual genotyping by the MassArray
genotyping system (Sequenom). Individual allelic and genotypic
frequencies showed significant association with asthma for 36
SNPs (allelic P,0.05. Table S1–S2 in File S1), showing a 97%
concordance between pooled GWAS and individual genotyping
results. More than half of the identified candidate genetic loci were
in significant LD with known genes from the Refseq database, or
directly located inside introns or coding sequences (Table S1 in
File S1). The most significant cluster as determined by average
silhouette score statistic is located inside the coding sequence of
Complement component 5 gene (C5) that is already known as an
asthma susceptibility gene reported in previous studies [29]. It is
localized on chromosome 9q33.2, in LD with two other genes that
regulate inflammation and significantly associated with allergic
asthma, GSN and RAB14.
Biological relevance towards asthma physiopathology was
supported by gene expression analysis of experimental asthma
mouse models and literature-based functional studies of annotated
Pooled GWAS Analysis on Pediatric Allergic Asthma
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16912Figure 1. Data analysis pipeline. Asthma and RC samples were divided in 4 pools of 31–36 elements, labeled and hybridized to Mapping 500K
SNP arrays. Different pools were replicated three times to account for tecnical and manual variability. Data were filtered, silhouette statistics was
applied and top 1% SNP was mapped onto UCSC genome browser and only clusters of at least two SNPs with a genomic physical distance ,30 Kb
were retained. Cluster-adapted silhouette threshold was calculated by averaging reshuffled random cluster silhouette scores.
doi:10.1371/journal.pone.0016912.g001
Figure 2. Details of cluster crossvalidation results. Silhouette average score for each cluster is shown as black circles and silhouette average
score threshold calculated by random score reshuffling as red dashed lines.
doi:10.1371/journal.pone.0016912.g002
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harboring risk alleles are expressed differentially in asthmatic vs
control mice in two different experimental asthma models (house
dust mite or ovalbumin challenge, Figure 3) and have a role in
the two key pathways involved in asthma physiopathology
(Table 2): airway smooth muscle contraction or bronchoconstric-
tion (RYR2, TACR3, CHRM2, PDE5A) [30–33] and regulation of
the pleiotropic mechanisms of inflammation, as modulation of
Th2 adaptive immunity and chemotaxis (C5, GSN, IPCEF1),
antigen processing (CPVL, PDIA6, PTPLB), cytokine production
(LPAR1, FXR1, NFKBIZ) [34–42].
To identify the candidate genetic loci more likely related to
allergic asthma onset, we individually genotyped the 24 top
scoring SNPs associated with known genes in an independent
validation set. RYR2, CHRM2 and TNS3 polymorphysms were
confirmed as associated with allergic asthma onset risk in an
independent pediatric population (Table S3 in File S1).
Discussion
We report here the first pooled genome-wide association study
of childhood allergic asthma along with the description of an
analysis pipeline that efficiently identified candidate genetic loci
linked to asthma development. Indeed the pooling approach poses
limitations compared to individual genotyping, that range from
the inflation of experimental error due to pooling construction, to
the inability to adjust for population stratification and the lack of
haplotype and subphenotype data. We addressed the first two
points by performing multiple technical replicates of each subpool,
and by checking the distribution of ancestry-informative SNPs
through principal component analysis [24].
GWAS from pooled DNA samples follow generally a two-stage
design in which candidates showing putative association are
confirmed by individual genotyping [23]. However, while the
statistics to identify the most significant candidates are well defined
in GWAS from individual samples, there is no widespread
agreement on which analysis pipeline should be used to prioritize
SNPs for individual genotyping in pooled GWAS. Few studies
explored the efficacy of different methods in selecting candidates;
among them Pearson et al. compared many statistical methods and
verified that the silhouette score was the most efficient method to
rank SNPs [10]. However, Bosse ` et al. using silhouette statistics on
T2DM dataset analyzed by pooled and individual genotyping
documented just 30–40% concordance between the two methods
[14]. However the authors also claim that a combination of
silhouette scores with ‘‘absolute difference’’ testing is superior to
silhouette analysis alone for validation studies including fewer than
1000 SNPs. Abraham et al. found 68% concordance, with the
cluster method based on physical distance on the genome as the
single best method [43]. These publications confirm that statistical
tests are inadequate to reveal the most pertinent candidate SNPs in
a pooled GWAS. While combination with absolute difference can
help identifying those markers having the higher allele frequency
variations between the two groups (and indeed absolute difference
calculated on the 36 significant SNPs reported in our study is high,
ranging from 0.086 to 0.24), combination with physical distance
on the genome addresses the almost unique feature of SNP
association studies, in which statistical association of one marker to
a phenotype is expected to be shared with other markers inside a
definite LD block. To address these points in the current study we
used a modular approach to identify the most significant loci
associated with asthma by combining silhouette statistics and
physical distance method with cluster-adapted thresholding; in this
way we found 97% concordance between pooled and individual
genotyping, with 36 out of 37 top-scoring SNP significant at the
individual genotyping level.
Moreover the most significant SNP is located inside the coding
sequence of C5, that was already identified as an asthma
Figure 3. Gene expression profiling of experimental asthma. In two models of experimental asthma induced by Ovalbumin or House dust
mite challenge in BALB/c mice there are significant differences in the expression of some genes identified in the GWAS study. Differential gene
expression is shown as mean, maximum and minimum of log2 ratios of allergen-challenged vs control mice.
doi:10.1371/journal.pone.0016912.g003
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candidate genes regulate functions that are relevant to bronchial
physiopathology, as immune- or inflammation-mediated mecha-
nisms and airway smooth muscle contraction. Lastly, the high
correlation with gene expression data in experimental asthma
models (42%) further supports the results, since genetic variation is
known to influence gene expression [44], and gene expression
difference itself was proposed as an efficient method to refine the
identification of candidate genes and functions in GWAS
experiments [45]. Lastly, three out of 24 candidate SNPs located
inside known genes were found significantly associated with
asthma in an independent validation set.
In this study we identified candidate genetic variants that
distinguish, within a population of allergic children, the subjects
with and without asthma; these differences may be due to the
differences between nasal and bronchial mucosa physiopathology,
that may subtend different genetic pathways between asthma and
rhinitis. In fact, even if upper and lower airways may be considered
as a unique entity supporting the concept of a ‘‘united airways’’ [46],
and are influenced by a common, evolving inflammatory process
that may be sustained and amplified by interconnected mechanisms,
there are many differences between nose and bronchi: smooth
muscle is present from the trachea to the bronchioles explaining
bronchoconstriction in asthma, cholinergic nerves are the predom-
inant bronchoconstrictor pathway, a-adrenergic agonists are
effective nasal vasoconstrictors in rhinitis whereas b2-adrenergic
agonists are effective bronchodilators in asthma and many others.
Differences between children with and without asthma are
evident from the analysis of the 269 patients recruited for the study
from the clinical and allergometric evaluation; actually asthmatic
children have higher total IgE values, higher specific IgE values and
higher prevalence of sensitization to house dust mite than patients
withRCwithoutasthmaticsymptoms.Wesuggestthat theseclinical
and immunological differences reflect an intrinsic genetic diversity
in the immunological mechanism of allergic response.
This is the first study done so far in which asthmatic children
have been compared not to the healthy population but to allergic
subjects with RC. By considering allergic children as the control
group, we excluded any interferences of genes involved in the
generic mechanisms of allergy, that mainly regulate the mecha-
nisms of inflammation, alteration of epithelial and mucosal
functions and modulation of the immune response to environ-
mental factors, thus identifying only new potential genetic pathway
explaining lower airway involvement. The limitation of using the
RC population as control group is related to the possible later
onset of asthma; however, since the mean age of the patients
enrolled in the study is significantly higher than the onset age of
asthma (P,0.0001), we can consider it a very unlikely event.
The vast majority of the identified candidate SNPs were not
previously reported, apart from C5 (Complement component 5) whose
polimorphisms were already associated with asthma development
[29]. The anaphylatoxin C5a is found in high concentrations in
the bronchoalveolar lavage fluid of asthmatics and mice with
experimentally induced asthma; it can induce smooth muscle
contraction,mucussecretion,increasedmicrovascular permeability,
leukocyte migration and activation, and degranulation of mast cells
[47]. Moreover a very recent publication showed that signalling by
complement factor C5a plays a key role in the development and
severityofasthma,throughtheinhibition ofIL-17-producinghelper
T cells and airway hyper-responsiveness [48]. Here we further
supported the association on C5 with allergic asthma and
furthermore suggested that the entire 9q33.2 region harbouring
also Gelsolin and Rab14 is associated with asthma, thus identifying
new candidate risk alleles in genes regulating inflammation and
immunomodulation.
Indeed almost all of the candidate genes identified up to now
belong to functional categories (innate immunity and immuno-
regulation, Th2 differentiation and effector function, mucosal
immunity) implicated both in asthma physiopathology and allergic
response in the upper airways and mucosa, very few of the
identified genes regulate functions peculiar only of the asthmatic
response (bronchial hyperresponsiveness and bronchoconstriction)
[1]. Here we suggested for the first time that allergic children that
develop or not asthma are genetically different, and that many of
the predisposing genes regulate functions (airway smooth muscle
contraction) that are uniquely relevant to asthma physiopathology
and not to allergy. Indeed the fact that RYR2 and CHRM2
polymorphisms were already confirmed as significant in an
independent validation set supports the view that genes regulating
bronchoconstrictions should be given more attention than those
regulating immune mechanisms that are relevant also to allergic
manifestations in the upper airways. However a larger validation
study is warranted to better define the most relevant target genes.
In summary, we described a new method of analysis of pooled
GWAS data that proved to be efficient in identifying significant
candidate SNPs associated to asthma onset within an allergic
pediatric population and report a list of candidate susceptibility
genes whose genetic variability appears to be associated to an
increased risk of asthma development in children already carrying
a genetic predisposition to allergic diseases.
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